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Abstract
8-Oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodGuo) is the most investigated oxidatively
damaged DNA lesion product that has been associated with the development of aging, cancer, and
some degenerative diseases. Here, we present the first LC-MS/MS method that enables the
simultaneous

measurement

of

its

repair

products

in

plasma

and

saliva,

namely

8-oxo-7,8-dihydroguanine (8-oxoGua) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodGuo).
Using this method, we investigated the underlying transport mechanism of oxidatively damaged
DNA between cellular compartments and biological matrices. Plasma, saliva and urine samples
were collected concurrently from 57 healthy subjects. Various deproteinization methods were
evaluated and the precipitants acetonitrile and sodium hydroxide-methanol were respectively
selected for plasma and saliva samples due to their effect on recovery efficiencies and
chromatography. The mean baseline concentrations of 8-oxoGua and 8-oxodGuo in plasma were
demonstrated to be 0.21 and 0.016 ng/mL, while in saliva they were 0.85 and 0.010 ng/mL,
respectively. A relatively high concentration of 8-oxoGua was found in saliva with a concentration
factor (CF, concentration ratio of saliva to plasma) of 4 as compared to that of 8-oxodGuo (CF:
0.6), implying that 8-oxoGua in plasma may be actively transported to saliva whereas 8-oxodGuo
was most dependent on a passive diffusion. Good correlations between urine and plasma
concentrations were observed for 8-oxoGua and 8-oxodGuo, suggesting that blood was a suitable
matrix in addition to urine. Significant correlation between 8-oxoGua and 8-oxodGuo in urine was
only observed when the concentrations were not corrected for urinary creatinine, raising the issue
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of applicability of urinary creatinine to adjust 8-oxoGua concentrations.

Key words: online SPE LC-MS/MS, oxidatively damaged DNA, plasma, saliva, deproteinization,
transport mechanism

Abbreviations:

8-oxoGua,

8-oxo-7,8-dihydro-2′-deoxyguanosine;

8-oxo-7,8-dihydroguanine;
LC-MS/MS,

liquid

8-oxodGuo,

chromatography-tandem

mass

spectrometry; CF, concentration factor; BER, base excision repair; ELISA, enzyme-linked
immunosorbent assay; SPE, solid-phase extraction; ESI, electrospray ionization; LOQ, limit of
quantification.
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Introduction
Oxidatively damaged DNA is understood to be involved in the development of aging, cancer, and
some

degenerative

diseases

(Cooke

et

al.

2006;

Tudek

et

al.

2010).

8-Oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodGuo) is an important DNA lesion product that can
be generated in cellular DNA by hydroxyl radicals, singlet oxygen, and one-electron oxidants
(Cadet et al. 2012). The detection of this DNA lesion product is considered important because of
its abundance and mutagenic potential through G-to-T transversions during DNA replication
(Cheng et al. 1992). It is generally accepted that oxidatively damaged DNA can be repaired, and
the repair products are released into the bloodstream and consequently appear in the urine without
further metabolism (Fraga et al. 1990). The modified nucleobase 8-oxo-7,8-dihydroguanine
(8-oxoGua) and modified 2′-deoxyribonucleoside (8-oxodGuo) in urine represent the major repair
products of oxidatively damaged DNA in vivo, presumably through the base excision repair (BER)
and sanitization of the 2′-deoxyribonucleotide pool (Evans et al. 2010) although, to date, the
precise source of urinary 8-oxodGuo remains unclear. Urinary 8-oxodGuo has been widely studied
and used as a biomarker of oxidative stress (Analysis et al. 2010), whereas limited information is
available concerning urinary 8-oxoGua. The reasons for this include previous studies which show
that diet could contribute significantly to its urinary levels (Fraga et al. 1990) and the poor stability
and solubility of 8-oxoGua which make it difficult to measure accurately (Helbock et al. 1998).
However, two robust studies in humans have shown that urinary levels of 8-oxodGuo and
8-oxoGua are not influenced by diet (Cooke et al. 2005; Gackowski et al. 2001) and the stability of
4

8-oxoGua has also been recently examined and found to be fairly stable (∼87 days in water with
pH of ∼7 or ∼112 days in 5% methanol with pH of 11, at -20 °C) (Hu et al. 2010a). Furthermore,
several reliable chromatographic-based methods have been developed for its detection in urine (Hu
et al. 2010a; Roszkowski and Olinski 2012; Svoboda et al. 2006; Weimann et al. 2002). We believe
that the detection of both 8-oxodGuo and 8-oxoGua in urine may improve the assessment of the
whole-body burden of oxidative stress.
In addition to urinary analysis, several studies reported that the measurement of 8-oxodGuo in
blood or saliva could also be useful; 8-oxodGuo concentrations in blood (e.g., serum) could
directly reflect exposure to oxidative stress and subsequent DNA repair in the whole organism
(Bloomer and Fisher-Wellman 2008; Sova et al. 2010), while salivary 8-oxodGuo could be
specific for oxidative stress in the buccal cavity (Agha-Hosseini et al. 2012; Sezer et al. 2012) or
whole organism (Komatsu et al. 2013; Su et al. 2012). However, most 8-oxodGuo measurements
in blood and saliva have been performed by enzyme-linked immunosorbent assay (ELISA) that is
known to be limited by a lack of specificity and sensitivity (Barregard et al. 2013). There is only
one chromatographic-based approach that has successfully quantified 8-oxodGuo in blood and
saliva (Bogdanov et al. 1999). To the best of our knowledge, there are no literature reports of the
modified nucleobase 8-oxoGua being quantified in plasma or saliva. A strength of the
measurement of 8-oxoGua in human body fluids is a much clearer understanding of its source,
compared to 8-oxodGuo, namely the BER pathways (e.g. via human 8-oxoguanine DNA
glycosylase 1).
5

Previously, we developed an isotope-dilution LC-MS/MS method coupled with online
solid-phase extraction (SPE) for simultaneous determination of 8-oxoGua and 8-oxodGuo in urine
(Hu et al. 2010a). In the present study, we attempted to extend this to the quantification of both
8-oxoGua and 8-oxodGuo in plasma and saliva. By doing so, we tried (i) to evaluate the feasibility
of using other biomatrices (i.e., blood or saliva) other than urine, (ii) to investigate the correlation
between the modified nucleobase 8-oxoGua and the most frequently measured biomarker of
oxidative stress, 8-oxodGuo, and (iii) to explore the underlying transport mechanism of
oxidatively damaged DNA in human body fluids.

Experimental
Chemicals
Solvents and salts were of analytical grade. Unlabeled 8-oxoGua and 8-oxodGuo were purchased
from

Sigma-Aldrich

and

the

stable

isotope

internal

standard,

[15N5]-8-oxo-7,8-dihydro-2′-deoxyguanosine ([15N5]-8-oxodGuo) was from Cambridge Isotope
Laboratories. The [15N5]-8-oxo-7,8-dihydroguanine ([15N5]-8-oxoGua) was synthesized as
described previously (Hu et al. 2010a).

Subjects and sample collection
This study was approved by the Institutional Review Board of Chung Shan Medical University.
Spot urine samples, and corresponding blood and saliva samples were concurrently collected from
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57 apparently healthy individuals. A questionnaire was used to obtain data on age and body mass
index (BMI). Blood samples were collected in EDTA vacutainer tubes and centrifuged at 3000 × g
for 15 min to separate plasma. For saliva collection, all the subjects were asked to rinse their
mouths with distilled water three times. Saliva was then collected by rolls of cotton wool, followed
by centrifugation at 3000 × g for 10 min. All samples were kept at 4 °C during sampling and then
stored at -20 °C prior to analysis.

Simultaneous determination of 8-oxoGua and 8-oxodGuo in urine
8-OxoGua and 8-oxodGuo concentrations in urine were measured using a validated method of
LC-MS/MS with online SPE as previously reported by Hu et al. (2010a). Briefly, a 20 μL of urine
was diluted 10 times with a solution containing 4 ng of [15N5]-8-oxoGua and 0.8 ng of
[15N5]-8-oxodGuo as internal standards in 5% (v/v) methanol (MeOH)/1 mM ammonium acetate
(AA). A 50 μL of prepared urine sample was directly injected into the online SPE LC-MS/MS.
After automated sample cleanup, LC-MS/MS analysis was performed using an Agilent 1100 series
HPLC system (Agilent Technology) interfaced with an API 3000 triple-quadrupole mass
spectrometer (Applied Biosystems, Foster City, CA, USA) with electrospray ion source (ESI). The
samples were analyzed in the positive ion multiple reaction monitoring mode, and the transitions
of the precursors to the product ions were as follows: m/z 168→140 (quantifier ion) and m/z 168→
112 (qualifier ion) for 8-oxoGua, m/z 173→145 for [15N5]-8-oxoGua, m/z 284→168 (quantifier ion)
and 284 → 140 (qualifier ion) for 8-oxodGuo, and m/z 289 → 173 (quantifier ion) for
7

[15N5]-8-oxodGuo. Urinary creatinine was determined using a HPLC-UV method (Yang 1998).

Simultaneous determination of 8-oxoGua and 8-oxodGuo in plasma and saliva
For plasma and saliva samples, four different deproteinization methods were evaluated including
precipitation with organic solvents (MeOH or acetonitrile), zinc sulfate-sodium hydroxide
(ZnSO4-NaOH) (Polson et al. 2003) and sodium hydroxide-methanol (NaOH-MeOH) (Bogdanov
et al. 1999). The detailed procedures are given in Supplementary Data I. Among these four
deproteinization methods, deproteinization by acetonitrile (ACN) and NaOH-MeOH generally
gave higher peak areas of both 8-oxoGua and 8-oxodGuo in plasma and saliva in the
chromatograms (as shown in Supplementary Data I, Fig. S1 for plasma and Fig. S2 for saliva). The
overall process efficiency of each deproteinization method was provided in Supplementary Data I
(Table S1); the overall process efficiency (combination of the matrix effect and the pretreatment
process recovery) was calculated from the ratio of the peak area of internal standard
([15N5]-8-oxoGua or [15N5]-8-oxodGuo) spiked before pretreatments to the peak area of internal
standard in neat solution multiplied by 100 (Matuszewski et al. 2003). Although deproteinization
by ACN and NaOH-MeOH gave higher process efficiencies, it was also noted that the retention
time during chromatography was not stable (it should be the same as that in the neat solution) (see
Fig. S1 and S2). A manual SPE using C18 cartridge was therefore applied after protein
precipitation by ACN or NaOH-MeOH to further purify the plasma and saliva samples.
Supplementary Data I (Table S2) showed the overall process efficiency of [15N5]-8-oxoGua and
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[15N5]-8-oxodGuo in plasma and saliva after combined pretreatment with protein precipitation and
manual SPE. Regarding a satisfactory process efficiency and chromatography for both 8-oxoGua
and 8-oxodGuo, the protein precipitation by ACN and NaOH-MeOH were finally selected and
applied for plasma and saliva samples, respectively, followed by the manual SPE, as described
below:
For plasma analysis, 1 mL of plasma was added with 40 μL of internal standard solution
containing 4 ng of [15N5]-8-oxoGua and 0.8 ng of [15N5]-8-oxodGuo. After addition of 3 mL of
ACN, the samples were mixed and centrifuged at 3000 ×g for 10 min. The supernatant was dried
and resuspended in 1 mL of deionized water. After addition of 0.3 mL of 1 M AA buffer (pH 5.25)
and vigorous vortexing, the sample was loaded onto a Sep-Pak C18 cartridge (100 mg/1 mL;
Waters, Milford, MA, USA) preconditioned with 1 mL of MeOH and 1 mL of deionized water.
The cartridge was then eluted with 1 mL of 40% MeOH. The eluate was dried under vacuum and
redissolved in 150 μL of 5% (v/v) MeOH containing 1 mM AA.
For saliva analysis, after addition of 40 μL of internal standard solution, aliquots of 2 mL of
saliva samples were precipitated with 2 mL of 1 mM NaOH in MeOH and centrifuged for 10 min
at 3000 ×g. The pellets were resuspended in 2 mL of MeOH and centrifuged for 10 min at 3000 ×g.
The supernatants were combined, dried and resuspended in 1 mL of deionized water, adjusted to
pH 7 with HCl. The resulting solutions were then processed for manual SPE as described earlier
for plasma.
Pretreated plasma and saliva samples were analyzed using the same validated method of online
9

SPE LC-MS/MS as previously reported by Hu et al. (2010a) with a minor modification in
chromatography gradient. An injection volume of 70 μL was used for plasma and saliva analysis.

Statistical methods
Mean and SD were used to describe the distributions of 8-oxoGua and 8-oxodGuo in urine, plasma
and saliva as well as the demographic data for study subjects. The data were analyzed using the
SAS statistical package (SAS, ver. 9.1). Pearson correlation coefficients were used to study the
relationships between 8-oxoGua or 8-oxodGuo concentrations in urine, plasma and saliva. The
concentration factor (CF) was used to investigate the possible transport mechanism for 8-oxoGua
and 8-oxodGuo, by dividing the mean 8-oxoGua (or 8-oxodGuo) concentration in urine (or saliva)
by its mean concentration in plasma (Haeckel and Hanecke 1996).

Results
Simultaneous determination of 8-oxoGua and 8-oxodGuo in plasma and saliva using online SPE
LC-MS/MS
A representative online SPE LC-MS/MS chromatogram for 8-oxoGua and 8-oxodGuo in saliva of
a healthy subject is shown in Fig. 1, while a representative online SPE LC-MS/MS chromatogram
for plasma analysis is in Supplementary Data II Fig. S3. The positive electrospray ionization mass
spectrum of 8-oxoGua contained a [M+H]+ precursor ion at m/z 168 and product ions at m/z 140
(quantifier ion, Fig. 1A) and m/z 112 (qualifier ion, Fig. 1B) due to losses of one or two CO groups
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(28 u or 56 u); a precursor ion at m/z 173 and product ion at m/z 145 characterized the
[15N5]-8-oxoGua (Fig. 1C). Meanwhile, the [M+H]+ precursor ion of 8-oxodGuo was m/z 284 and
product ions appeared at m/z 168 (quantifier ion, Fig. 1D) and m/z 140 (qualifier ion, Fig. 1E),
resulting from loss of the neutral 2′-deoxyribose moiety (116 u) or its combination with CO (28 u);
a precursor ion at m/z 289 and product ion at m/z 173 characterized the [15N5]-8-oxodGuo (Fig. 1F).
The retention times were 9 min and 13 min for 8-oxoGua and 8-oxodGuo, respectively.
The limit of quantification (LOQ) was estimated for a signal-to-noise (S/N) ratio of 10 from
the sample chromatograms at the lowest validation level tested, using the quantification transition.
Because 8-oxoGua and 8-oxodGuo are usually present in body fluid, there was no blank matrix
available. In the present study, LOQ values were estimated from quantified levels present in
non-spiked blank samples (Gracia-Lor et al. 2011). Using the present method, the LOQs in plasma
were determined to be 0.04 and 0.008 ng/mL for 8-oxoGua and 8-oxodGuo, respectively, while the
LOQs in saliva were 0.02 ng/mL for 8-oxoGua and 0.003 ng/mL for 8-oxodGuo. Overall process
efficiencies (combination of the matrix effect and the pretreatment process recovery, Matuszewski
et al. 2003) of 8-oxoGua and 8-oxodGuo in plasma were estimated to be 26-35 % and 74-88%,
respectively, while they were 24-36 % for 8-oxoGua and 61-78% for 8-oxodGuo in saliva. It has to
be mentioned that any variation in overall process efficiency is well compensated by the use of
stable isotope internal standards added and therefore will not influence the accuracy of
measurement.
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8-OxoGua and 8-oxodGuo concentrations in plasma, saliva and urine
A total of 57 healthy subjects were recruited into the study. As shown in Table 1, the mean age and
BMI of the subjects were 30.2 ± 6.9 years and 23.7 ± 5.4 kg/m2, respectively. The overall mean
concentrations of 8-oxoGua and 8-oxodGuo in plasma were 0.21 ± 0.09 and 0.016 ± 0.005 ng/mL,
respectively. Salivary concentrations of 8-oxoGua and 8-oxodGuo were 0.85 ± 0.76 and 0.010 ±
0.007 ng/mL, respectively, while urinary 8-oxoGua and 8-oxodGuo were 11.9 ± 4.1 and 3.6 ± 1.3
ng/mg creatinine. Concentration distributions of 8-oxoGua and 8-oxodGuo in three matrices are
plotted in Fig. 2.
The correlations between different matrices for 8-oxoGua (or 8-oxodGuo) concentrations were
analyzed using Pearson correlation coefficients. It was found that the urinary 8-oxoGua
concentrations were significantly correlated with the 8-oxoGua concentrations in plasma (r =
0.291, P = 0.028, see Fig. 3A). Urinary 8-oxodGuo concentrations were also correlated with
8-oxodGuo in plasma (r = 0.737, P < 0.001, Fig. 3B). No significant correlations were found
between saliva and urine or saliva and plasma for both 8-oxoGua as well as 8-oxodGuo.
Furthermore, the correlation between 8-oxoGua and 8-oxodGuo in each matrix was also
investigated. As shown in Fig. 4, the best correlation between 8-oxoGua concentrations and
8-oxodGuo concentrations was obtained in urine (r = 0.67, P < 0.001), followed by plasma (r =
0.425, P = 0.001) and then saliva (r = 0.377, P = 0.004).

Discussion
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We have successfully applied isotope-dilution LC-MS/MS coupled online SPE to quantify both
8-oxoGua and 8-oxodGuo in three human body fluids. To the best of our knowledge, this is the
first report describing an assay to simultaneously determine levels of both 8-oxoGua and
8-oxodGuo in plasma and saliva.
Previous analytical methods were focused mostly on the quantification of 8-oxodGuo in urine,
with some attempts to measure the 8-oxodGuo concentrations in blood or in saliva. Breton et al.
(2003) used HPLC-ECD to measure 8-oxodGuo in human serum but failed to provide a
satisfactory result due to the lack of validated pretreatment of serum. Lam et al. (2012) used
UPLC-MS/MS with prior manual SPE purification to determine the 8-oxodGuo concentrations in
plasma and saliva. The authors found that mean 8-oxodGuo in plasma was 0.04 ng/mL whereas the
8-oxodGuo in saliva was not detectable. In the present study, we have simultaneously quantified
the 8-oxodGuo and 8-oxoGua both in saliva and plasma. This success is partly attributed to the use
of our online SPE system, but also effective sample pretreatment which removed interfering
compounds and decreased possible matrix effects.
The mean baseline plasma concentrations of 8-oxodGuo detected in this study (~0.016 ng/mL)
for healthy adults were similar to the findings obtained by HPLC-ECD and LC-MS/MS (~
0.013-0.040 ng/mL) (see Table 2), whereas they were considerably lower than those obtained by
ELISA kits (up to ~5.9 ng/mL) (Pan et al. 2008; Sato et al. 2010). A similar discrepancy was also
noted for salivary 8-oxodGuo analysis (~0.016 ng/mL in this study vs. up to 42.7 ng/mL by ELISA
kit) (Su et al. 2009). The latest report by the European Standards Committee on Urinary (DNA)
13

Lesion Analysis (ESCULA) clearly demonstrates that ELISA kits are not specific for 8-oxodGuo
in urine, giving urinary 8-oxodGuo values 2–6 times higher than those measured by
chromatographic methods (Barregard et al. 2013). This study further suggested that the
overestimation of 8-oxodGuo by ELISA assay may be more severe in plasma or saliva samples by
over hundred times higher than those measured by chromatographic methods. Such phenomena
could be due to extremely low concentrations of 8-oxodGuo, coupled with the presence of high
molecular weight compounds, such as carbohydrates or proteins, which may interfere with the
ELISA, as suggested elsewhere (Evans et al. 2008).
Despite the clear provenance of 8-oxoGua in body fluids, from the BER of DNA, its presence
in body fluids has been much less studied, compared to 8-oxodGuo. Possible contributions from
diet or RNA notwithstanding, this could be partly related to analysis of 8-oxoGua being more
technically challenging than 8-oxodGuo. Furthermore, no ELISA kit exist for 8-oxoGua, whereas a
number of commercial kits are available for 8-oxodGuo, which are relatively cheap and do not
require specific technical skills or equipment. Nevertheless, recent studies have suggested that
urinary excretion of 8-oxoGua is a promising biomarker of oxidatively damaged DNA. For
instance, Loft et al. (2012) showed an increased risk of developing lung cancer among
non-smokers with high excretion of 8-oxoGua. Increased 8-oxoGua excretion has been associated
with exposure to air pollution, toxic metals, tobacco smoke and low plasma antioxidant levels
(Suzuki et al. 1995; Yoshioka et al. 2008; Foksinski et al. 2007). Svoboda et al. (2006) showed that
urinary excretion of 8-oxoGua was associated with life span and further suggested that urinary
14

8-oxoGua may be a better marker of oxidative stress than urinary 8-oxodGuo. In the present study,
in addition to urinary 8-oxoGua, we also reported mean baseline concentrations of 8-oxoGua in
plasma and saliva (Table 2), with this being the first report of salivary 8-oxoGua levels in the
literature.
It was noted that the mole ratios of 8-oxoGua to 8-oxodGuo varied greatly among the three
body fluids (see Table 1). For instance, the mole ratio of 8-oxoGua to 8-oxodGuo was 23.5:1 in
plasma whereas it was lower (5.8:1) in urine. This suggested that 8-oxodGuo was excreted more
efficiently from blood by the kidney than 8-oxoGua; the CF of 58 and 238 can be obtained for
8-oxoGua and 8-oxodGuo, respectively, by dividing the mean 8-oxoGua (or 8-oxodGuo)
concentration in urine by its mean concentration in plasma (Supplementary Data III, Fig. S4).
Interestingly, the mole ratio of 8-oxoGua to 8-oxodGuo was much higher in saliva (217:1) than
that of in plasma (23.5:1). Because the 8-oxodGuo concentrations in saliva were similar to those of
in plasma (CF: 0.6), we propose that passive diffusion could be the major transport route for
8-oxodGuo passing between plasma and saliva. Although a recent review has suggested that
endogenous and exogenous compounds transferred into saliva by passive diffusion show the
strongest correlation between plasma and saliva concentrations (Michalke et al. 2014), such
correlation between plasma and saliva concentrations for 8-oxodGuo was not observed in our
study. One of reasons could be possibly due to that 8-oxodGuo is weakly acidic with pKa of 8.6
(Culp et al. 1989), and small changes of salivary pH during sampling will affect ionization and the
distribution of such weak acid across the epithelial membrane (Haeckel 1993), influencing the
15

correlation between plasma and saliva concentrations. In contrast to 8-oxodGuo in saliva, much
higher concentrations of 8-oxoGua were found in saliva with a CF of 4 (Supplementary Data III,
Fig. S4), implying a different transport mechanism for 8-oxoGua. There may be three possible
explanations for this; (i) a proportion of 8-oxoGua in saliva could derive from BER in cells of the
oral mucosa, (ii) part of 8-oxoGua in saliva might also result from the degradation of oral mucosa
cells during cell turnover since turnover rate of oral mucosa is approximately 2-3 times higher than
that of epidermis of the skin (Winning and Townsend 2000), and (iii) 8-oxoGua is actively
transported from plasma to saliva. It is difficult to prove that the BER reaction of oral mucosa
could contribute to the 8-oxoGua in saliva. To test the other two hypotheses, two experiments were
conducted (Supplementary Data IV and V). As DNA, released during cell turnover, might be
further degraded to nucleobases by processes present in saliva, we therefore incubated calf thymus
DNA (or 8-oxodGuo standard) with saliva at 37 °C for 4 h to investigate whether the enzymes in
saliva are able to degrade the calf thymus DNA (or 8-oxodGuo standard) into nucleobases and
consequently release 8-oxoGua. The results showed that after a 4 h incubation at 37 °C 8-oxoGua
concentrations in saliva spiked with calf thymus DNA (or 8-oxodGuo standard) were similar to
those of saliva without spiking (Supplementary Data IV, Table S3). This result demonstrated that if
oral mucosal cells were degraded during cell turnover, the enzymes in saliva are not able to release
8-oxoGua from DNA (or 8-oxodGuo) and therefore could not contribute the 8-oxoGua in saliva.
To explore the final hypothesis, we measured the structural analogs of 8-oxoGua and 8-oxodGuo,
respectively, namely guanine (Gua, the native nucleobase) and 2′-deoxyguanosine (dGuo, the
16

native 2′-deoxyribonucleoside) in plasma, saliva and urine, to investigate whether the structural
analogs of 8-oxoGua or 8-oxodGuo were higher in saliva than that of in plasma, implying an
active transport mechanism. Interestingly, the result (Supplementary Data V, Table S4) showed that
the mean concentration of Gua in saliva (mean: 59 ng/mL) was also higher than that of in plasma
(mean: 16 ng/mL) with a CF of 3.7 (Supplementary Data V, Fig. S5), which was similar to that
observed for 8-oxoGua (CF: 4, Supplementary Data III, Fig. S4). These results implied that both
native and oxidized Gua are actively transported from plasma to saliva. Meanwhile, we found that
the mean concentration of Gua (59 ng/mL, Supplementary Data V, Table S4) is only 69-times
higher than 8-oxoGua (0.85 ng/mL in Table 1) in saliva. This result also supports our above
finding that the degradation of oral mucosa cells cannot be the primary source of salivary
8-oxoGua; otherwise the ratio between native and oxidized bases would be similar to that seen in
cells, reportedly anywhere between 0.3-6 8-oxoGua/106 Gua (Gedik et al. 2005; Dziaman et al.
2009). Taken together, the most likely explanation for the high concentration of 8-oxoGua
measured in saliva could be due to the active transportation for 8-oxoGua (and Gua) from plasma
to saliva, but the possibility cannot be ruled out that 8-oxoGua in saliva could originate from BER
in the cells of the buccal cavity.
As shown in Fig. 2, we noted that the distribution range of 8-oxoGua concentration in plasma
was narrow but became relatively wide in urine when adjusted for urinary creatinine. However,
this phenomenon was not observed for 8-oxodGuo as the concentration distributions in plasma and
urine displayed a comparable distribution range. Moreover, Fig. 3A showed only a modest
17

correlation between 8-oxoGua concentration in plasma and in urine adjusted with urinary
creatinine (r = 0.291; P = 0.028), whereas a strong correlation was observed for 8-oxodGuo
concentration in plasma and in urine adjusted with urinary creatinine, as shown in Fig. 3B (r =
0.737; P < 0.001). The above findings indicated that the use of urinary creatinine to adjust urinary
flow for urinary 8-oxoGua concentration could be questionable, but it is appropriate for urinary
8-oxodGuo concentration. This result, showing that the suitability of using creatinine
concentration for urinary 8-oxodGuo, is consistent with a previous finding reported by Barregard
et al. (2013). The inapplicability of creatinine for urinary 8-oxoGua correction may also explain
why a satisfactory correlation between 8-oxoGua and 8-oxodGuo in urine was only observed
without adjustment for urinary creatinine (Fig. 4C). There was no correlation between 8-oxoGua
and 8-oxodGuo after adjustment for urinary creatinine (data not shown, P = 0.09).

Conclusion
We have successfully quantified both 8-oxoGua and 8-oxodGuo in plasma, saliva and urine
samples using online SPE LC-MS/MS. Among these three biomatrices, urine, being non-invasive,
easy to collect and handle (less biohazard than blood sample), together with its direct measurement
should be considered the best specimen, especially in large-scale studies. Alternatively, plasma
samples may also be considered applicable as the concentrations of 8-oxoGua (or 8-oxodGuo) in
plasma were significantly correlated with those in urine (see Fig. 3) although additional sample
pretreatment is required. However, a previous report has suggested that plasma levels of
18

8-oxodGuo are not valid measures of oxidative stress (Poulsen et al. 2014). The authors state that
because the level in plasma is determined mainly by the kidney function and not by the level of
oxidative stress. Therefore when comparing different individuals the measure will not provide
information about oxidative stress, but kidney function. We suggest that because molecules are
excreted into the urine mainly by an active transport mechanism, impaired kidney function will not
only influence the plasma level but also the urinary level, even a 24 h urine sample is collected.
Therefore, if the kidney argument holds true for plasma, then it also applies to urine. This
reiterates the importance of kidney function and determining urinary creatinine values as a
surrogate for function. Saliva samples are not recommended for oxidative stress assessment in this
study, because the source of oxidative DNA lesion products in saliva is not fully understood so far,
especially for 8-oxoGua. As the concentrations of 8-oxoGua are highly correlated with 8-oxodGuo
either in plasma or in urine (see Fig. 4), both lesion products and matrices should be considered to
be good biomarkers of oxidative stress in humans. The greater 8-oxoGua concentration in plasma
and urine (compared to 8-oxodGuo) is an additional advantage to its accurate measurement, but
concerns remain over its correction by creatinine in urine. In addition to providing the analytical
techniques in plasma and saliva analysis, the findings obtained in this study may help to add new
insights into the transport of oxidatively DNA lesions between cellular compartments and
biological matrices.
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Table 1 Demographic characteristics and mean 8-oxoGua/8-oxodGuo concentrations of study
subjects
Variable

Subjects (n = 57)

Age (y)

30.2 ± 6.9

BMI (kg/m2)

23.7 ± 5.4

In plasma (ng/mL),
8-oxoGua

0.21 ± 0.09

8-oxodGuo

0.016 ± 0.005

8-oxoGua/8-oxodGuoa

23.5 ± 10.4

In saliva (ng/mL),
8-oxoGua

0.85 ± 0.76

8-oxodGuo

0.010 ± 0.007

8-oxoGua/8-oxodGuo

217 ± 127

In urine (ng/mg creatinine),
8-oxoGua

11.9 ± 4.1 (12.2 ± 6.5)b

8-oxodGuo

3.6 ± 1.3 (3.8 ± 2.5)

8-oxoGua/8-oxodGuo
a

The ratio expressed in mol/mol

b

as expressed in ng/mL

5.8 ± 1.9
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Table 2 Concentrations of 8-oxoGua and 8-oxodGuo in various biomatrices for healthy subjects in the literature, as measured by chromatographic based
methods.
Matrix

a

8-oxoGua

8-oxodGuo

Methods

References

Plasma/serum

-a

0.0134 ± 0.002

HPLC-ECD

Bogdanov et al. (1999)

(ng/mL)

0.160

-

HPLC-ECD

Shin et al. (2001)

-

0.022 ± 0.009

Online SPE LC-MS/MS

Hu et al. (2010b)

-

0.040 ± 0.014

UPLC-MS/MS

Lam et al. (2012)

0.21 ± 0.09

0.016 ± 0.005

Online SPE LC-MS/MS

This study

Saliva

-

0.0153 ± 0.003

HPLC-ECD

Bogdanov et al. (1999)

(ng/mL)

-

0.005 ± 0.003

Online SPE LC-MS/MS

Hu et al. (2010b)

0.85 ± 0.76

0.010 ± 0.007

Online SPE LC-MS/MS

This study

Urine

11 ± 2.4

3.9 ± 2.0

HPLC-ECD

Svoboda et al. (2006)

(ng/mg creatinine)

11.4

3.5

HPLC-GC/MS

Obtulowicz et al. (2010)

11.9 ± 4.7

4.4 ± 2.1

Online SPE LC-MS/MS

Hu et al. (2010a)

11.9 ± 4.1

3.6 ± 1.3

Online SPE LC-MS/MS

This study

Not measured
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Figure legends
Fig. 1. LC-MS/MS coupled with online SPE chromatograms for 8-oxoGua (A-C) and 8-oxodGuo
(D-F) in human saliva. Selected reaction-monitoring transitions of (A) m/z 168→140 and (B) m/z 168
→112 for 8-oxoGua, (C) m/z 173→145 for [15N5]-8-oxoGua, (D) m/z 284→168 and (E) m/z 284→
140 for 8-oxodGuo, and (F) m/z 289→173 for [15N5]-8-oxodGuo. cps, counts per second.

Fig. 2. Distribution of 8-oxoGua and 8-oxodGuo concentrations in urine, plasma and saliva.

Fig. 3. Correlations between plasma and urine concentrations for (A) 8-oxoGua and (B) 8-oxodGuo.

Fig. 4. Correlations between 8-oxoGua and 8-oxodGuo in (A) plasma, (B) saliva and (C) urine.
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